Raptor Pharmaceutical Corp. (NASDAQ:RPTP):
The company’s RSI reading has hit 58.81. The stock edged higher by 0.91% to close previous trading session at USD 4.44.
The shares of the company fluctuated in the range of USD 2.94 and USD 16.28 in the course of 52 weeks. Over the three months, the company’s shares have declined by -14.78% and in the past one year, it has lost -61.49%. Additionally, the stock’s year to date performance has declined -14.62%. Over the last five days its shares have surged by 14.14% and in the past six months it has moved down -32.83%.
Further, the stock is at a price to book ratio of 3.22. The stock’s weekly volatility is calculated as 8.57% and monthly volatility as 8.82% with ATR of 0.33, beta of 0.95and price to cash ratio of 2.40.
Raptor Pharmaceutical Corp. (RPTP) on March 21, 2016 announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC):
The stock increased by 5.07% to close last trading session at USD 59.71. The company’s shares oscillated in the range of USD 55.38 and USD 59.91 during intraday trade.
A total of 743,700 shares exchanged hands, below its 3 month average volume of 1.05 million shares. Over the last five days its shares have surged by 2.56% and in the past six months it has moved down -52.17%.
Furthermore, the stock has weekly volatility of 6.97% and monthly volatility of 7.17% with ATR of 4.93. The stock’s RSI is 42.77 and distance from 50-day simple moving average is -16.86%, whereas its distance from 20-day simple moving average is -2.81% and distance from 200-day simple moving average is -42.57%.
Anacor Pharmaceuticals Inc (ANAC) on March 22, 2016 announced that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor’s New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is January 7, 2017.